Administration strategies and smart devices for drug release in specific sites of the upper GI tract.

Targeting the release of drugs in specific sites of the upper GI tract would meet local therapeutic goals, improve the bioavailability of specific drugs and help overcoming compliance-related limitations, especially in chronic illnesses of great social/economic impact and involving polytherapies (e.g. Parkinson's and Alzeimer's disease, tubercolosis, malaria, HIV, HCV). It has been traditionally pursued using gastroretentive (GR) systems, i.e. low-density, high-density, magnetic, adhesive and expandable devices. More recently, the interest towards oral administration of biologics has prompted the development of novel drug delivery systems (DDSs) provided with needles and able to inject different formulations in the mucosa of the upper GI tract and particularly of esophagus, stomach or small intestine. Besides comprehensive literature analysis, DDSs identified as smart devices in view of their high degree of complexity in terms of design, working mechanism, materials employed and manufacturing steps were discussed making use of graphic tools. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Marco Uboldi, Alice Melocchi, Saliha Moutaharrik, Luca Palugan, Matteo Cerea, Anastasia Foppoli, Alessandra Maroni, Andrea Gazzaniga, Lucia Zema. Administration strategies and smart devices for drug release in specific sites of the upper GI tract. Journal of controlled release : official journal of the Controlled Release Society. 2022 Aug;348:537-552

Mesh Tags

PMID: 35690278

search → result